Aastrom Biosciences to Present at Multiple Conferences in April

Tue Apr 9, 2013 4:12pm EDT

* Reuters is not responsible for the content in this press release.


ANN ARBOR, Mich., April 9, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the
leading developer of patient-specific expanded multicellular therapies for the treatment of
severe, chronic cardiovascular diseases, today announced that the company will be presenting at
the following scientific and investor meetings in April:

1st Annual Regen Med Investor Day


April 17, 2013


Harmonie Club, New York, NY


* 9:00 a.m. EDT - Dr. Ronnda Bartel, chief scientific officer of Aastrom, will participate in a
panel discussion entitled "Clinical Outlooks in Cardiovascular Disease."
* 1:45 p.m. EDT - Nick Colangelo, president and CEO of Aastrom, will provide an overview of the
company and its development programs.

19th Annual International Society for Cellular Therapy (ISCT) Meeting


April 22-25, 2013


SKYCITY Auckland Convention Center, Auckland, New Zealand


* April 23rd - Dr. Bartel will present "Commercialization Strategies for Ixmyelocel-T, a Novel
Autologous Therapy for Severe, Chronic Cardiovascular Disease."
* April 24th - Poster presentation titled "Effects of Ixmyelocel-T on Murine Bleomycin-Induced
Lung Fibrosis."
* April 24th - Poster presentation titled "Phase 3 Readiness for Autologous Cell Therapies: Unique
Software Applications for Training, Scheduling and Manufacturing of Ixmyelocel-T."
* April 25th - Dr. Kelly Ledford, scientist at Aastrom, will present "Potential Atheroprotective
Effects of Ixmyelocel-T Cellular Therapy."

12th Annual Needham & Company Healthcare Conference


April 30, 2013


Westin Grand Central Hotel, New York, NY


10:00 a.m. EDT - Mr. Colangelo will provide an update on the company's clinical programs and
progress in research and development.

About Aastrom Biosciences

Aastrom Biosciences is the leader in developing patient-specific, expanded multicellular therapies
for use in the treatment of patients with severe, chronic cardiovascular diseases. The company's
proprietary cell-processing technology enables the manufacture of ixmyelocel-T, a patient-specific
multicellular therapy expanded from a patient's own bone marrow and delivered directly to damaged
tissues. Aastrom has advanced ixmyelocel-T into late-stage clinical development, including a Phase
2b clinical trial in patients with ischemic dilated cardiomyopathy. For more information, please
visit Aastrom's website at www.aastrom.com

The Aastrom Biosciences, Inc. logo is available at

This document contains forward-looking statements, including, without limitation, statements
concerning clinical trial plans and progress, objectives and expectations, clinical activity
timing, intended product development, the performance and contribution of certain individuals and
expected timing of collecting and analyzing treatment data, all of which involve certain risks and
uncertainties. These statements are often, but are not always, made through the use of words or
phrases such as "anticipates," "intends," "estimates," "plans," "expects," "we believe," "we
intend," and similar words or phrases, or future or conditional verbs such as "will," "would,"
"should," "potential," "could," "may," or similar expressions. Actual results may differ
significantly from the expectations contained in the forward-looking statements. Among the factors
that may result in differences are the inherent uncertainties associated with clinical trial and
product development activities, regulatory approval requirements, competitive developments, and
the availability of resources and the allocation of resources among different potential uses.
These and other significant factors are discussed in greater detail in Aastrom's Annual Report on
Form 10-K, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange
Commission. These forward-looking statements reflect management's current views and Aastrom does
not undertake to update any of these forward-looking statements to reflect a change in its views
or events or circumstances that occur after the date of this release except as required by law.

CONTACT: Media contact
         Andrea Coan
         Berry & Company
         (212) 253-8881
         Investor contact
         Chad Rubin
         The Trout Group
         (646) 378-2947